Right on the heels of nailing a $40 million upfront for its oncology R&D collaboration deal with Eli Lilly and bringing its tally of cash raised to $180 million with an ambitious venture round, Yale spinout NextCure has laid the scientific foundation for the immuno-oncology company in a new preclinical study just published in Nature Medicine.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.Free Subscription